Big Diabetes Pharma – the winners!

In the contrast to the collective name “Big Pharma” which refers to all pharmaceutical fields I would propose a new term “Big Diabetes Pharma” – top 5 companies which monopolize the diabetes market: Novo Nordisk , Sanofi , MannKind, and the diabetes partnership of Bristol-Myers Squibb  and AstraZeneca.

 Only 5 companies! Amazing. Unbelievable huge profits:

The diabetes treatment business is booming. According to the Centers for Disease Control and Prevention, 25.8 million Americans are affected by diabetes. That's more than 8% of the U.S. population. S&P's Rating Services estimates that the global diabetes market will grow to 280 million people in the next 20 years, elevating sales of diabetes-related treatments from $35 billion to $58 billion.

Well, monopoly and cartel are extremely profitable systems and they are basically the main target in business wars. Those 5 companies are clearly winners! My congratulations! But what about the diabetes patients? Who cares?!